Sugi Predict

Sugi Predict / Targets / PLA2G2C

PLA2G2C

Putative inactive group IIC secretory phospholipase A2 · Q5R387 · PLA2G2C on Sugi Atlas →

20,053 patent compounds predicted against PLA2G2C, 12,257 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL592891 SCHEMBL592891 0.53 7/20
SCHEMBL466059 SCHEMBL466059 0.51 7/20
SCHEMBL109880 SCHEMBL109880 0.47 6/20
SCHEMBL109881 SCHEMBL109881 0.47 6/20
SCHEMBL111415 SCHEMBL111415 0.47 6/20
SCHEMBL111416 SCHEMBL111416 0.47 6/20
SCHEMBL112093 SCHEMBL112093 0.47 6/20
SCHEMBL112094 SCHEMBL112094 0.47 6/20
SCHEMBL114110 SCHEMBL114110 0.47 6/20
SCHEMBL114111 SCHEMBL114111 0.47 6/20
SCHEMBL121326 SCHEMBL121326 0.47 6/20
SCHEMBL121327 SCHEMBL121327 0.47 6/20
SCHEMBL468782 SCHEMBL468782 0.44 6/20
SCHEMBL468783 SCHEMBL468783 0.44 6/20
SCHEMBL468769 SCHEMBL468769 0.47 5/20
SCHEMBL468770 SCHEMBL468770 0.47 5/20
SCHEMBL468828 SCHEMBL468828 0.47 5/20
SCHEMBL468829 SCHEMBL468829 0.47 5/20
SCHEMBL410388 SCHEMBL410388 0.44 4/20
SCHEMBL314576 SCHEMBL314576 0.43 4/20

Clinical trials — most relevant to PLA2G2C by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL) PHASE4COMPLETED
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy PHASE3COMPLETED
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes PHASE3UNKNOWN
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study PHASE2/PHASE3RECRUITING
Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy PHASE3UNKNOWN
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Lovaza's Effect on the Activation of Platelets PHASE2COMPLETED
Anti-CD38 Antibody Treating APS With Thrombocytopenia PHASE2RECRUITING
Belimumab With Rituximab for Primary Membranous Nephropathy PHASE2RECRUITING
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
TP10 Use in Patients With C3 Glomerulopathy (C3G) PHASE1WITHDRAWN
An Outcome Analysis of Primary Membranous Nephropathy nanRECRUITING
Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy nanCOMPLETED
Investigation of Secreted Phosphoproteins and PiP3 (Phosphoinositolphospat 3) in Sputum nanCOMPLETED
Immunopathological Analysis in a French National Cohort of Membranous Nephropathy nanRECRUITING
Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke nanCOMPLETED
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN
Correlation and Clinical Utility of Urinary Biomarker in Membranous Glomerulonephritis nanUNKNOWN
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity. nanUNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Mucomyst for Hepatitis C nanSUSPENDED
Positron Emission Tomography (PET) to Study Brain Signaling nanCOMPLETED
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly nanUNKNOWN
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Mechanistic Insights From Bronchoscopy Airway Samples nanRECRUITING
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study nanCOMPLETED
Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PLA2G2C binder may also engage these)

ProteinNameSimilarity
P48076 — 0.972 P48076 →
P39878 — 0.967 P39878 →
Q9Z0Y2 — 0.954 Q9Z0Y2 →
PLA2G2E Group IIE secretory phospholipase A2 0.954 landscape →
P06596 — 0.948 P06596 →
P00594 — 0.947 P00594 →
P14419 — 0.947 P14419 →
P00593 — 0.946 P00593 →
P00592 — 0.945 P00592 →
PLA2G1B Phospholipase A2 0.945 landscape →
P04055 — 0.945 P04055 →
PLA2G2D Group IID secretory phospholipase A2 0.944 landscape →
Q99P27 — 0.944 Q99P27 →
Q9WVF6 — 0.940 Q9WVF6 →
Q9QUL3 — 0.940 Q9QUL3 →
PLA2G12B Group XIIB secretory phospholipase A2-like pr 0.939 landscape →
P04416 — 0.938 P04416 →
Q6EER6 — 0.935 Q6EER6 →
PLA2G10 Group 10 secretory phospholipase A2 0.935 landscape →
Q2YHJ2 — 0.933 Q2YHJ2 →
Q71QE8 — 0.933 Q71QE8 →
Q8IZN7 — 0.932 Q8IZN7 →
Q90W39 — 0.932 Q90W39 →
Q9QXX3 — 0.932 Q9QXX3 →
Q8S8N6 — 0.932 Q8S8N6 →
Q2YHJ7 — 0.932 Q2YHJ7 →
Q8N323 — 0.931 Q8N323 →
A7VL23 — 0.931 A7VL23 →
Q6H3C5 — 0.931 Q6H3C5 →
Q8JIY9 — 0.931 Q8JIY9 →